The objective of the study was to formulate and evaluate sustained release polymeric tablets of ketoprofen for the release rate, release patterns and the mechanism involved in the release process of the drug. Formulations with three different types of newly synthesized polymers and one grade of ethyl cellulose ether derivatives (FP100 premium) in several drug-to-polymer ratios (D:P ratio 10:1, 10:2 and 10:3) were compressed into tablets using the direct compression method. They were examined for their physical properties and appearance. Tablets dimensional tests (thickness, diameter) and Q.C tests (hardness, friability, disintegration) were performed according to the USP methods. For in vitro drug release studies of Ketoprofen controlled release (CR) tablets, the USP Method-1 (Rotating Basket Method) was used with Pharma test dissolution apparatus (D-63512 Hainburg, Germany). The medium used for dissolution was phosphate buffer having a pH of 7.4 kept at constant temperature of 37±1°C. In order to analyze the drug release kinetics from each of the prepared matrices, five different mathematical models were applied to the release data including zero order kinetics, first order kinetics, Higuchi kinetics, Hixson Crowell kinetics and Korsmeyer Peppas equations were applied to the release data. The results obtained from different parameters showed that polymers: Polyglycolide, PGA-cocaprolactone, PGA-co-pentadecalactone and Ethocel FP100 premium can be used successfully in order to develop directly compressed prolonged release tablets of slightly soluble drugs such as ketoprofen. Particle size of polymer is a determining factor in controlling the release of ketoprofen from tablets. Ethocel standard FP100 polymers extend the release rates of drug more efficiently than the conventional granular form of the other three polymers. Further, the three new polymers and Ethocel FP100 could efficiently extend the release of the drugs as compared to the reference conventional formulation.
INTRODUCTION
Efforts have been made in drug delivery system, e.g. targeted drug delivery system in which the drug is active in targeted area of the body to which it is targeted and sustained release formulation in which the drug is released over a period of time in controlled manner and specific time interval from the product (Drug Delivery, *Corresponding author: E-mail: suj55@yahoo.com. Tel: +92-300-9382344.
2007
). Ketoprofen is a drug belonging to the group of nonsteroidal anti-inflammatory drugs (NSAIDs). It is a propionic acid derivative and is used in the treatment of rheumatoid arthritis. Its chemical formula is given as 2-benzoyl-3-phenyl propionic acid (Liversidge, 1981) . Like other NSAIDs, ketoprofen is used in clinics as an antiinflammatory and analgesic drug for the treatments of rheumatoid arthritis and osteoarthritis (Therapeutic Drug Volume, 1991) . Ketoprofen has advantages over other NSAIDs because it has no or very little addictive potential and also has no effect on sedation and depression of respiration (Green, 2001) .
NSAIDs including ketoprofen have poor tolerability profile having some adverse effects (Evans, 1996) . Due to inhibition of COX-1, various side effects are produced; whereas, on the inhibition of COX-2, their therapeutic effects are developed (Villegas et al., 2004) . Some common adverse effects are gastrointestinal tract complaints such as nausea, vomiting and epigastric discomfort. Certain nervous system disorders include headache, drowsiness and dizziness, and also lower gastro intestinal tract infection (Vavra, 1987) .
Certain studies were performed in mice, rats and dogs, etc, in which rats were found to exhibited gastrointestinal tract (GIT) and renal system toxicity (Kantor, 1986) . Dogs were also found to be susceptible for ulceration and irritation of GIT but no carcinogenic effect was found in standard screening assays (Kantor, 1986) .
To overcome these adverse effects, it was thought to prepare controlled release matrix formulations of ketoprofen using three newly synthesized polymers along with one ethyl cellulose ether derivatives (Ethocel FP100 premium) for comparison. Ethocel standard FP premium is the new product; it exists in a very fine particle form, thus allowing the use of direct compression to incorporate into the controlled release matrix Zhu, 2001a, Wahab et al., 2011) . The new polymers, if made into fine particles will give more extended release which can be used as polymers of choice in CR formulations in future. We also studied other viscosity grades of polymer Ethocel, and data is already published, (Jan et al., 2011) and only one grade compared (FP 100) with the newly synthesized polymers.
The objective of the study was to formulate and evaluate sustained release polymeric tablets of ketoprofen for the release rate, release patterns and the mechanism release rate, release patterns and the mechanism involved in the release process of the drug.
METHODOLOGY

Material and chemicals
Monobasic potassium phosphate, NaOH, (Merck, Germany), ketoprofen, lactose, magnesium stearate (BDH Chemical Ltd, Pool England), polymers polyglycolic acid (PGA), PGA-co-caprolactone, PGA-co-pentadecalactone and Ethocel FP100 Premium, Pharma test dissolution apparatus (D-63512, Hainburg), UV-Visible spectrophotometer (UVIDEC-1601 Shimadzu, Japan), single punch tablet machine (Erweka AR 400, Germany), hardness tester (Erweka Apparatus TB24, Germany), friability tester (Erweka TA3R, Germany).
Construction of standard calibration curve
20 mg of ketoprofen was taken in a 100 ml volumetric flask for the preparation of stock solutions in 100 ml phosphate buffer (pH 7.4). The drug was dissolved using ultra-sonifier. This stock solution was used for further dilutions. 50 ml of this stock solution was taken in a 100 ml volumetric flask and 50 ml of the buffer was added to increase the volume to 100 ml. The concentration of the drug in this first dilution was 0.1 mg/ml. Then from this dilution, 50 ml was taken and further diluted to 100 ml, where the buffer the drug concentration in solution was 0.5 mg/ml. Similarly 0.025, 0.0125 and 0.00625 mg/ml dilutions were prepared in the same way. These dilutions were then analyzed at 258 nm using UV visible spectrophotometer.
Formulation development
200 mg tablet of ketoprofen containing 100 mg drug and three new types of polymers and Ethocel FP100 premium grade at drug to polymer ratio of 10:1, 10:2, and 10:3 were developed. Lectose was used as filler and 0.5% magnisium stearate was used as a lubricant. The formulations are given in Table 1 .
Preparation of tablets
The drug and polymer were weighed and mixed using mortar and pestle, and then filler was added and mixed. All these ingredients were passed through 30 mesh sieve screen. Lubricant was added in the end, then again passed twice through the same sieve, and were directly compressed in tablets using single punch tablet machine (Erweka AR 400, Germany).
Physical characterization of the tablets
After the tablet preparation, the quality control tests were carried out for each formulation. These tests includes, hardness test performed for ten tablets according to USP method, using hardness tester (Erweka, Germany).The dimensional tests of the tablets were performed using Vernier caliper according to USP method. The friability test was carried out in a friabilator on 20 tablets from each formulation. Disintegration test was performed on six tablets from each formulation, using disintegration apparatus. All the physical tests performed were within established ranges.
In vitro drug release study
For dissolution study, Pharma test dissolution apparatus (D-63512 Hainburg, Germany) was used. Rotating basket (USP method I) was adopted for the dissolution study of all tablet formulations. For ketoprofen, the dissolution media used was 7.4 pH phosphate buffer. Temperature of dissolution medium was maintained at 37± 0.5°C and the rotating speed was 100 rpm. Samples of 5 ml were taken at time intervals of 0.5, 1, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0 10.0, 12.0, 18.0 and 24 h and filtered using filter paper of 0.45 µm. Then all samples were observed spectrophotometrically (UV visible spectrophotometer 1601, Shimadzu) and their respective absorbances were noted. Then, the percent release was calculated for all tablets from the standard curves.
Drug release kinetics investigation
The following kinetic models and equations were applied on the data obtained from in vitro dissolution studies of different matrix tablets formulations to determine the release kinetics (Table 2) .
Statistical analysis
Statistical analysis were performed, using computer based excel program for calculation of mean and standard deviation. 
RESULTS AND DISCUSSION
Drug release studies
Drug release studies were carried out on all formulations after the dissolution study conducted on each formulation. The release profile of ketoprofen tablets containing different types of polymers, that is, PGA, PGAco-caprolactone, PGA-co-pentadecalactone and Ethocel FP100 premium in different ratios of 10:1, 10:2 and 10:3, is given in Figures 1 to 3 . Figure 4 shows comparison of conventional tablets of ketoprofen and reference SR tablets of Ketoprofen with the prepared ketoprofen matrix tablets with drug to polymer ratio of 10:2 of different polymers. From the Figures 1, 2 and 3 , it can be observed that the prepared matrix formulations of ketoprofen showed reduced release profiles from that of the standard conventional tablets of the respective drugs. These figures also showed that the release profile is more decreased in case of the tablets containing FP premium grades of Ethocel 100 as compared to other polymers which have comparatively larger particles. It can be observed from these figures that those formulations containing three new polymers showed about 95 to 98% release of the drug from tablet in 24 h; whereas, in case of Ethocel FP100 premium it showed less release in 24 h. Swelling of the matrix tablets occurred during the dissolution. This may be due to hydrating property of the polymer which eventually leads to the swelling of the tablet. Due to this swelling phenomena, the polymer's glass transition temperature (Tg), the dissolution solvent provides a stress due which there is relaxation response in the polymer-chains and this create an increase in the distance between the polymer-chains (Khan and Zhu, 2001a ). An increase in the molecular volume is produced in the hydrated polymer, due to which free volume is diminished because of the presence of microspores. This could be a shift in release mechanism of the drug from polymer. A lot of other researchers and investigators also observed the same results when they were performing their studies (Khan and Zhu, 2001 ).
In vitro drug release kinetics
Drug release kinetics for each matrix was analyzed using the modals discussed earlier. Tables 3, 4 was also greater than 0.5. it indicates that the ketoprofen formulations shows anomalous-non Fickian drugdiffusion. These results confirming with the findings of Amit (2010) , in whose investigation on zidovudine release from guar gum matrix tablets, shows a higher value of n, that is, n > 0.5. Here, the author ( mechanism of the drug release was a result of coupling of two mechanisms, that is, erosion and diffusion. The formulation containing Ethocel® standard FP100 premium showed better release kinetics as compared to other formulations containing different grades of polymers. Table 4 . Release kinetics of controlled release tablets of Ketoprofen + PGA, PGA-co-CL, PGA-co-PDL and Ethocel FP100 at drug to polymer ratio (D:P) of 10:2 in pH 7.4 phosphate buffer. 
Conclusion
The results obtained from different parameters showed that polymers: polyglycolide, PGA-cocaprolactone, PGA-co-pentadecalactone and Ethocel FP100 Premium can be used successfully in order to develop directly compressed prolonged release tablets of slightly soluble drugs such as ketoprofen. Particle size of polymer is a determining factor in controlling the release of ketoprofen from tablets. Ethocel standard FP100 polymers extend the release rates of drug more efficiently then the conventional granular form of the other three polymers. Further, the three new polymers and Ethocel FP100 could efficiently extend the release of the drugs as compared to the reference conventional formulation. The new polymers, if made into fine particles will give more extended release which can be used as polymers of choice in CR formulations in the future.
